JAMP Pharma

The JAMP Pharma Group, a leader in the Canadian pharmaceutical industry, announces the launch of PrJAMP Enzalutamide (Enzalutamide oral capsules) in Canada, strengthening its commitment to improving access to critical prostate cancer therapies. With this

The JAMP Pharma Group, a leader in the Canadian pharmaceutical industry, announces the launch of PrJAMP Nintedanib (nintedanib, oral capsules) in Canada, reinforcing its commitment to improving access to essential therapies for interstitial lung diseases.

JamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients wor

The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.

Jamteki TM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JA

--Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group, a Canadian owned pharmaceutical organization headquartered in the Greater Montreal area, announced

Expanded partnership covers biosimilar candidates in immunology and oncology REYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture o

/CNW Telbec/ - JAMP Pharma Corporation ("JAMP") is voluntarily, on a precautionary basis, recalling one product lot of Atorvastatin tablets, 40 mg, 100-format...